Loading clinical trials...
Loading clinical trials...
A Multi-center, Long-term, Open-label Extension Study of [S,S]-Reboxetine (PNU-165442G) Administered Once Daily in Patients With Fibromyalgia
Conditions
Interventions
[S,S]-Reboxetine
Locations
109
United States
Pfizer Investigational Site
Birmingham, Alabama, United States
Pfizer Investigational Site
Phoenix, Arizona, United States
Pfizer Investigational Site
Tucson, Arizona, United States
Pfizer Investigational Site
Elk Grove, California, United States
Pfizer Investigational Site
Fullerton, California, United States
Pfizer Investigational Site
Lafayette, California, United States
Start Date
May 1, 2008
Primary Completion Date
May 1, 2009
Completion Date
May 1, 2009
Last Updated
December 17, 2019
NCT07226648
NCT07358754
NCT05901259
NCT03759522
NCT07398417
NCT07230171
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions